Loading...
XNAS
PBYI
Market cap402mUSD
Jul 09, Last price  
7.90USD
1D
-2.83%
1Q
1.54%
Jan 2017
-74.27%
IPO
-39.23%
Name

Puma Biotechnology Inc

Chart & Performance

D1W1MN
XNAS:PBYI chart
P/E
12.92
P/S
1.76
EPS
0.61
Div Yield, %
—
Shrs. gr., 5y
5.06%
Rev. gr., 5y
0.29%
Revenues
228m
-0.91%
0000-281,0960000027,700,000251,000,000272,260,000225,110,000253,155,000228,031,000235,637,000230,468,000228,371,000
Net income
31m
+2.75%
-15,093,000-14,083-16,836-15,976-10,232,878-74,300,000-54,659,000-142,000,000-239,300,000-276,000,000-292,000,000-113,600,000-75,595,000-59,995,000-29,126,0002,00021,591,00030,278,00031,111,000
CFO
42m
+7.41%
-15,093,000-11,834,000-16,815,000-18,246,000-1,825,018-44,000,000-55,048,000-77,200,000-154,500,000-141,700,000-172,500,000-24,100,00022,376,000800,00020,650,000-15,827,00027,009,00038,918,00041,802,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
URL
https://www.pumabiotechnology.com/
IPO date
Mar 21, 2012
Employees
192
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT